Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study.

Frenel, Jean‐Sébastien; Tourneau, Christophe Le; O’Neil, Bert H.; Ott, Patrick A.; Piha‐Paul, Sarina A.; Gomez‐Roca, Carlos; Brummelen, Emilie van; Rugo, Hope S.; Thomas, Shelia D.; Saraf, Sanatan; Chen, Mei; Varga, Andréa

doi:10.1200/jco.2016.34.15_suppl.5515

Cited by 56 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 24 subjects were treated with 10 mg/kg every 2 weeks for 24 months until to unacceptable toxicity, progress, withdrawal, or death. In this population with confirmed PD-L1 expression in greater than or equal to 1% of tumor or stroma cells by immunohistochemistry testing, the overall response rate was 12.5% [46]. Promising results in this population of advanced cervical cancer patients were heavily pretreated, with 62.5% had received two or more therapies for metastatic disease, and subsequently this agent has entered phase II study (NCI02628067).…”

Section: Five-year Viewmentioning

confidence: 92%

The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer

Minion

Tewari

2017

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Section: Five-year Viewmentioning

confidence: 92%

The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer

Minion

Tewari

2017

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

“…In the KEYNOTE-028 study, ORR to pembrolizumab was 12.5% [44]. Nivolumab, on the other hand, demonstrated ORR of 24% in patients with previously-treated metastatic anal cancer [45].…”

Section: Clinical Trialsmentioning

confidence: 99%

Advances in Cancer Immunotherapy in Solid Tumors

Menon

Shin

2016

Cancers

143

View full text Add to dashboard Cite

Immunotherapy is heralded as one of the most important advances in oncology. Until recently, only limited immunotherapeutic options were available in selected immunogenic cancers like melanoma and renal cell carcinomas. Nowadays, there is an improved understanding that anti-tumor immunity is controlled by a delicate balance in the tumor microenvironment between immune stimulatory and immune inhibitory pathways. Either by blocking the inhibitory pathways or stimulating the activating pathways that regulate cytotoxic lymphocytes, anti-tumor immunity can be enhanced leading to durable anti-tumor responses. Drugs which block the immune regulatory checkpoints namely the PD-1/PDL1 and CTLA 4 pathway have shown tremendous promise in a wide spectrum of solid and hematological malignancies, significantly improving overall survival in newly diagnosed and heavily pretreated patients alike. Hence there is renewed enthusiasm in the field of immune oncology with current research focused on augmenting responses to checkpoint inhibitors by combination therapy as well as studies looking at other immune modulators and adoptive T cell therapy. In this article, we highlight the key clinical advances and concepts in immunotherapy with particular emphasis on checkpoint inhibition as well as the future direction in this field.

show abstract

“…Preliminary results from the cervical cancer cohort of the KEYNOTE-028 study were recently presented and included patients with recurrent squamous cell carcinoma (SCC) of the cervix (NCT 02054806) [30]. In this study, treatment with anti-PD-1 therapy (pembrolizumab) demonstrated a 12.5% objective response rate with 3/24 patients having stable disease.…”

Section: Cervixmentioning

confidence: 99%

Immunotherapy in Gynecologic Cancers: Are We There Yet?

Pakish

Jazaeri

2017

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion statement Immune-targeted therapies have demonstrated durable responses in many tumor types with limited treatment options and poor overall prognosis. This has led to enthusiasm for expanding such therapies to other tumor types including gynecologic malignancies. The use of immunotherapy in gynecologic malignancies is in the early stages and is an active area of ongoing clinical research. Both cancer vaccines and immune checkpoint inhibitor therapy continue to be extensively studied in gynecologic malignancies. Immune checkpoint inhibitors, in particular, hold promising potential in specific subsets of endometrial cancer that express microsatellite instability. The key to successful treatment with immunotherapy involves identification of the subgroup of patients that will derive benefit. The number of ongoing trials in cervical, ovarian, and endometrial cancer will help to recognize these patients and make treatment more directed. Additionally, a number of studies are combining immunotherapy with standard treatment options and will help to determine combinations that will enhance responses to standard therapy. Overall, there is much enthusiasm for immunotherapy approaches in gynecologic malignancies. However, the emerging data shows that with the exception of microsatellite unstable tumors, the use of single-agent immune checkpoint inhibitors is associated with response rates of 10– 15%. More effective and likely combinatorial approaches are needed and will be informed by the findings of ongoing trials.

show abstract

Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study.

Cited by 56 publications

References 0 publications

The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer

The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer

Advances in Cancer Immunotherapy in Solid Tumors

Immunotherapy in Gynecologic Cancers: Are We There Yet?

Contact Info

Product

Resources

About